Sangamo Therapeutics Relocates Principal Executive Offices

TL;DR

Sangamo Therapeutics moved its main office to Richmond, CA.

AI Summary

On February 6, 2025, Sangamo Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 501 Canal Blvd., Richmond, California 94804. This move is part of the company's ongoing operations and reporting requirements.

Why It Matters

This filing indicates a change in Sangamo Therapeutics' operational base, which could signal strategic shifts or expansions within the company.

Risk Assessment

Risk Level: low — The filing is a routine administrative update regarding office location and does not contain information about financial performance, significant transactions, or regulatory actions.

Key Players & Entities

• Sangamo Therapeutics, Inc. (company) — Registrant
• February 6, 2025 (date) — Date of earliest event reported
• 501 Canal Blvd., Richmond, California 94804 (location) — New principal executive offices address
• 000-30171 (company_id) — SEC File Number

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value per share SGMO Nasdaq Global

Filing Documents

• sgmo-20250206.htm (8-K) — 60KB
• sgmo-20250206_g1.jpg (GRAPHIC) — 160KB
• sgmo-20250206_g2.jpg (GRAPHIC) — 386KB
• sgmo-20250206_g3.jpg (GRAPHIC) — 128KB
• sgmo-20250206_g4.jpg (GRAPHIC) — 73KB
• sgmo-20250206_g5.jpg (GRAPHIC) — 67KB
• sgmo-20250206_g6.jpg (GRAPHIC) — 70KB
• sgmo-20250206_g7.jpg (GRAPHIC) — 59KB
• sgmo-20250206_g8.jpg (GRAPHIC) — 174KB
• sgmo-20250206_g9.jpg (GRAPHIC) — 116KB
• 0001628280-25-004197.txt ( ) — 2976KB
• sgmo-20250206.xsd (EX-101.SCH) — 2KB
• sgmo-20250206_lab.xml (EX-101.LAB) — 21KB
• sgmo-20250206_pre.xml (EX-101.PRE) — 12KB
• sgmo-20250206_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On February 6, 2025, Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") announced updated preliminary clinical data from its Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease, in advance of a presentation at the 21 st Annual WORLD Symposium on February 6, 2025. A summary of the data is below. This announcement included data on the 33 patients treated with isaralgagene civaparvovec as of the data cutoff date of September 12, 2024. Enrollment and dosing are complete in the Phase 1/2 STAAR study. In October 2024, Sangamo announced that the FDA had provided a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding the requirement for an additional registrational study and accelerating estimated time to potential approval by approximately three years. The FDA agreed in a Type B interaction that data from the ongoing Phase 1/2 STAAR study can serve as the primary basis for approval under the Accelerated Approval Program, using eGFR slope at 52 weeks across all patients as an intermediate clinical endpoint. The 52-week eGFR slope data from all enrolled patients in the Phase 1/2 STAAR study is expected to be available in the first half of 2025. A potential Biologics License Application (BLA) submission is anticipated in the second half of 2025. Sangamo continues to advance business development discussions for a potential ST-920 collaboration agreement. Summary of Updated Preliminary Clinical Data from Phase 1/2 STAAR Study of Isaralgagene Civaparvovec Announced on February 6, 2025 in Advance of Presentation at 21 st Annual WORLD Symposium on February 6, 2025 The STAAR study is an ongoing Phase 1/2 multicenter, open-label, dose-ranging clinical study designed to assess a single infusion of isaralgagene civaparvovec in Fabry disease patients 18 years of age. Patient

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation: the safety and efficacy and therapeutic and commercial potential of isaralgagene civaparvovec; the presentation of clinical data from the Phase 1/2 STAAR study; the potential for isaralgagene civaparvovec to qualify for the FDA's Accelerated Approval program, including the adequacy of data generated in the Phase 1/2 STAAR study to support any such approval; expectations concerning the availability of additional data to support a potential BLA submission for isaralgagene civaparvovec, and the timing of such submission; the potential to accelerate the expected timeline to approval of isaralgagene civaparvovec; Sangamo's plans to seek a potential collaboration partner for ST-920; Sangamo's plans to participate in industry and investor conferences; and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo's lack of capital resources to obtain regulatory approval for and commercialize its product candidates in a timely manner or at all, including the ability to secure a collaboration partner for ST-920; the uncertain timing and unpredictable nature of clinical trial results, including the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, including that the 52-week data from the Phase 1/2 STAAR study will not support a BLA submission and/or that the 104-week data from such study will not verify the clinical

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SANGAMO THERAPEUTICS, INC. Dated: February 6, 2025 By: /s/ SCOTT B. WILLOUGHBY Name: Scott B. Willoughby Title: Senior Vice President, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR